About The Study
Study Location: Albuquerque, NM
Migraines are a common form of headache associated with intense throbbing or pulsing in one area of the head. They are often accompanied by nausea, vomiting, or severe sensitivity to light and sound. This debilitating condition can, for some sufferers, be accompanied by auras, which are flashes of light or blind spots.
Researchers are looking for adult participants with a minimum 1-year history of migraine attacks, with an average of 4 to 14 migraine days per month, to participate in a clinical research study evaluating the efficacy of an FDA-approved drug for the prevention of migraine attacks. Participants will be randomly assigned to receive either the study drug (Rimegepant) or a matching placebo. The placebo is a tablet that looks like the study drug but contains no active medication.
Study Criteria
To qualify, participants must:
- Be between the ages of 18 and 65
- Have a history of migraine attacks for at least 1 year, starting before age 50
- Have migraine attacks lasting, on average, 4-72 hours when untreated
- Have between 4 and 14 average migraine days per month
Why Participate?
There is no cost to participate and health insurance is not required to participate. Eligible participants will receive the FDA-approved study drug or placebo and all study-related assessments at no cost. Compensation for travel may also be provided.